We found that PRLR expression to be significantly downregulated in invasive breast cancer, only 21% of invasive cases showed detectable expression of the PRLR in comparison with normal/benign (80%) and in situ carcinoma (60%) (85). The gene discussed is PRLR; the disease is in situ carcinoma.